ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma (PLAT-04)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03244306
Recruitment Status : Active, not recruiting
First Posted : August 9, 2017
Last Update Posted : December 3, 2018
Sponsor:
Information provided by (Responsible Party):
Rebecca Gardner, Seattle Children's Hospital

Brief Summary:
Patients with relapsed or refractory leukemia often develop resistance to chemotherapy and some patients who relapse following CD19 directed therapy relapse with CD19 negative leukemia. For this reason, the investigators are attempting to use T-cells obtained directly from the patient, which can be genetically modified to express a chimeric antigen receptor (CAR) to CD22, a different protein from CD19, expressed on the surface of the leukemic cell in patients with CD22+ leukemia. The CAR enables the T-cell to recognize and kill the leukemic cell through the recognition of CD22, a protein expressed on the surface of the leukemic cell in patients with CD22+ leukemia. This is a Phase 1 study designed to determine the safety and feasibility of the CAR+ T - cells and the feasibility of making enough to treat patients with CD22+ leukemia.

Condition or disease Intervention/treatment Phase
Leukemia Biological: Patient-derived CD22-specific CAR T-cells also expressing an EGFRt Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-04: A Phase 1 Feasibility and Safety Study of CD22-CAR T Cell Immunotherapy for CD22+ Leukemia and Lymphoma
Actual Study Start Date : July 27, 2017
Estimated Primary Completion Date : June 15, 2019
Estimated Study Completion Date : June 15, 2034

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Leukemia

Arm Intervention/treatment
Experimental: Autologous CD22-specific CAR T-cells expressing EGFRt Biological: Patient-derived CD22-specific CAR T-cells also expressing an EGFRt
Patient-derived CD22-specific chimeric antigen receptor T-cells expressing an EGFRt




Primary Outcome Measures :
  1. The adverse events associated with one or multiple CAR T-cell product infusions will be assessed [ Time Frame: 30 days ]
    The type, frequency, severity, and duration of adverse events will be summarized

  2. The number of successfully and unsuccessfully manufactured and infused CAR T-cell products will be assessed [ Time Frame: 28 days ]
    Proportion of products successfully manufactured and infused



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   1 Year to 26 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • First 3 subjects: male and female subjects age ≥ 18 years and < 27 years
  • Subsequent subjects: 12 months of age and <27 years of age at the time of study enrollment
  • Disease status (one of the following):

    1. If post-allogeneic hematopoetic cell transplant (HCT): confirmed CD22+ leukemia recurrence, defined as ≥0.01% disease
    2. If Relapse/Refractory status with no prior history of allogeneic HCT, one of:

      • 2nd or grater marrow relapse, with or without extramedullary disease
      • 1st marrow relapse at end of 1st month of re-induction with marrow having ≥0.01% blasts by morphology and/or MPF
      • Primary Refractory, defined as >5% blasts by multi-parameter flow after ≥2 separate induction regimens
      • Subject has indication for HCT but is ineligible, inclusive of persistent minimal residual disease
    3. CD22+ Lymphoma refractory or relapsed with no known curative therapies available
  • Asymptomatic from CNS involvement, if present, and have a reasonable expectation that disease burden can be controlled in the interval between enrollment and T-cell infusion. Subjects with significant neurologic deterioration will not be eligible for T-cell infusion until stabilized.
  • Free from active GVHD and off immunosuppressive GVHD therapy for 4 weeks.
  • Lansky or Karnofsky performance score of ≥50
  • Life expectancy of >8 weeks
  • Recovered from acute toxic effects of all prior chemotherapy, immunotherapy, and radiotherapy
  • ≥7 days post last chemotherapy administration (excluding intrathecal or maintenance chemotherapy)
  • ≥7 days post last systemic corticosteroid administration
  • No prior virotherapy
  • Adequate organ function
  • Adequate laboratory values
  • Patients of childbearing/fathering potential must agree to use highly effective contraception
  • Signed a written consent

Exclusion Criteria:

  • Presence of active clinically significant CNS dysfunction
  • Pregnant or breastfeeding
  • Unable to tolerate apheresis procedure, including placement of temporary apheresis line if required
  • Presence of active malignancy other than CD22+ leukemia or lymphoma
  • Presence of active severe infection
  • Presence of any concurrent medical condition that would prevent the patient from undergoing protocol-based therapy
  • Presence of primary immunodeficiency/bone marrow failure syndrome
  • Unwilling to participate in 15-year follow-up period that is required if CAR T cell therapy is administered

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03244306


Locations
United States, Washington
Seattle Children's Hospital
Seattle, Washington, United States, 98105
Sponsors and Collaborators
Seattle Children's Hospital
Investigators
Study Chair: Corinne Summers, MD Seattle Children's Hospital

Responsible Party: Rebecca Gardner, Associate Medical Director, Immunotherapy Coordinating Center, Seattle Children's Hospital
ClinicalTrials.gov Identifier: NCT03244306     History of Changes
Other Study ID Numbers: PLAT-04
First Posted: August 9, 2017    Key Record Dates
Last Update Posted: December 3, 2018
Last Verified: November 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Rebecca Gardner, Seattle Children's Hospital:
leukemia
CD 22
CAR T cell
pediatric
young adult
chimeric antigen receptor

Additional relevant MeSH terms:
Leukemia
Neoplasms by Histologic Type
Neoplasms